Novartis AG (NVS)

115.64 +1.87 (+1.64%) At close: 04:00PM EDT

Novartis AG

Lichtstrasse 35
Basel 4056
Switzerland
41 61 324 1111
https://www.novartis.com

Sector(s): Healthcare
Industry: Drug Manufacturers - General
Full Time Employees: 76,057

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Vasant Narasimhan M.D.	Chief Executive Officer	8.7M	N/A	1976
Mr. Harry Kirsch	Chief Financial Officer	4.33M	N/A	1965
Mr. Victor Bulto	President of US	3.56M	N/A	1978
Dr. Patrick Horber M.D.	President of International	7.94M	N/A	1970
Dr. Steffen Lang Ph.D.	President of Operations	2.54M	N/A	1967
Paul Penepent	Head of Group Financial Reporting and Accounting	N/A	N/A	N/A
Ms. Sloan Simpson	Global Head of Investor Relations	N/A	N/A	N/A
Dr. Klaus Moosmayer Ph.D.	Chief Ethics, Risk & Compliance Officer	1.69M	N/A	1968
Ms. Karen L. Hale	Chief Legal Officer	2.55M	N/A	1968
Dr. Robert Kowalski Pharm.D.	Chief People & Organization Officer	2.28M	N/A	1968

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Corporate Governance

Novartis AG’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.